ALPHA JECT micro 6 emulsion for injection for Atlantic salmon

Authorised

- Infectious pancreatic necrosis virus, serotype Sp, Inactivated
- Moritella viscosa, Inactivated
- Aliivibrio salmonicida, Inactivated
- Vibrio anguillarum, serotype O2a, Inactivated
- Vibrio anguillarum, serotype O1, Inactivated
- Aeromonas salmonicida, subsp. salmonicida, Inactivated

Product identification

Medicine name:
ALPHA JECT micro 6 emulsion for injection for Atlantic salmon
ALPHA JECT micro 6 injeksjonsvæske, emulsjon til atlantisk laks

Active substance:
Infectious pancreatic necrosis virus, serotype Sp, Inactivated
Moritella viscosa, Inactivated
Aliivibrio salmonicida, Inactivated
Vibrio anguillarum, serotype O2a, Inactivated
Vibrio anguillarum, serotype O1, Inactivated
Aeromonas salmonicida, subsp. salmonicida, Inactivated

Target species:
Atlantic salmon

Route of administration:
Intraperitoneal use

Product details

Active substance and strength:
Infectious pancreatic necrosis virus, serotype Sp, Inactivated
0.28 antigen unit(s) / 0.05 millilitre(s)

Moritella viscosa, Inactivated
60.00 Relative Percentage Survival / 0.05 millilitre(s)

Aliivibrio salmonicida, Inactivated
90.00 Relative Percentage Survival / 0.05 millilitre(s)

Vibrio anguillarum, serotype O2a, Inactivated
75.00 Relative Percentage Survival / 0.05 millilitre(s)

Vibrio anguillarum, serotype O1, Inactivated
75.00 Relative Percentage Survival / 0.05 millilitre(s)

Aeromonas salmonicida, subsp. salmonicida, Inactivated
70.00 Relative Percentage Survival / 0.05 millilitre(s)

Pharmaceutical form:
Emulsion for injection

Withdrawal period by route of administration:
Intraperitoneal use:

- **Atlantic salmon**
  - Meat. 0 degree day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI10AL02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:
Norway

Available in:
Norway

Package description:
500 ml bag
250 ml bag
10x500 ml bag

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Pharmaq AS

Marketing authorisation date:
15/12/2011

Manufacturing sites for batch release:
Pharmaq AS

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
11-8504

Date of authorisation status change:
15/12/2011

Reference member state:

Norway

Procedure number:
NO/V/0008/001

Concerned member states:
Ireland United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Package Leaflet

English (PDF)
Published on: 22/10/2024
Download

Labelling

Summary of Product Characteristics

English (PDF)
Published on: 22/10/2024
Download

Combined File of all Documents